We are live on ! Find out more
GEVA

SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA

Delisted

GEVA was delisted on the 22nd of June, 2015.

Back to rankings

130 hedge funds and large institutions have $3.89B invested in SYNAGEVA BIOPHARMA CORP COM STK (DE) in 2015 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 56 increasing their positions, 41 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

37% more repeat investments, than reductions

Existing positions increased: 56 | Existing positions reduced: 41

21% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 19

15% more capital invested

Capital invested by funds: $3.37B → $3.89B (+$513M)

3% more funds holding

Funds holding: 126 → 130 (+4)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

68% less call options, than puts

Call options by funds: $21.7M | Put options by funds: $68.8M

Holders
130
Holders Change
+4
Holders Change %
+3.17%
% of All Funds
3.46%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
23
Increased
56
Reduced
41
Closed
19
Calls
$21.7M
Puts
$68.8M
Net Calls
-$47.1M
Net Calls Change
-$44M

Top Buyers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
+$106M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$102M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$57.9M
4
Capital Research Global Investors
Capital Research Global Investors
California
+$48.5M
5
Wellington Management Group
Wellington Management Group
Massachusetts
+$48.3M

Top Sellers

Rank Fund Capital Flow
1
CWAM
Columbia Wanger Asset Management
Illinois
-$63.7M
2
JHIU
Janus Henderson Investors US
Colorado
-$29.7M
3
BB
BB Biotech
Switzerland
-$11.1M
4
Invesco
Invesco
Georgia
-$10.8M
5
ACH
ArrowMark Colorado Holdings
Colorado
-$8.23M
Name Holding Trade Value Shares
Change 		Change in
Stake
ACH
26
ArrowMark Colorado Holdings
Colorado
$15.8M -$8.23M -77,690 -32%
Geode Capital Management
27
Geode Capital Management
Massachusetts
$15.4M +$3.25M +30,667 +24%
Allianz Asset Management
28
Allianz Asset Management
Germany
$14.5M -$6.66M -62,870 -30%
Bank of New York Mellon
29
Bank of New York Mellon
New York
$12.2M +$1.44M +13,582 +12%
Ameriprise
30
Ameriprise
Minnesota
$11.3M -$2.7M -25,545 -18%
Goldman Sachs
31
Goldman Sachs
New York
$11.2M +$127K +1,197 +1%
California Public Employees Retirement System
32
California Public Employees Retirement System
California
$8.03M – – –
GC
33
Guggenheim Capital
Illinois
$8M +$1.92M +18,123 +28%
TCIM
34
TIAA CREF Investment Management
New York
$7.72M +$418K +3,947 +5%
Charles Schwab
35
Charles Schwab
California
$7.3M +$1.79M +16,952 +29%
BIM
36
BlackRock Investment Management
Delaware
$7.25M +$1.72M +16,257 +28%
PC
37
Pier Capital
Connecticut
$5.95M +$2.51M +23,723 +64%
Macquarie Group
38
Macquarie Group
Australia
$5.91M +$1.01M +9,556 +19%
PAMU
39
Pictet Asset Management (UK)
United Kingdom
$5.56M -$3.81M -36,018 -37%
LI
40
LMCG Investments
Massachusetts
$5.5M +$3.11M +29,337 +109%
CS
41
Candriam SCA
Luxembourg
$5.37M +$1.59M +15,000 +38%
UBS AM
42
UBS AM
Illinois
$4.97M +$360K +3,400 +7%
D.E. Shaw & Co
43
D.E. Shaw & Co
New York
$4.91M +$5.33M +50,303 New
California State Teachers Retirement System (CalSTRS)
44
California State Teachers Retirement System (CalSTRS)
California
$4.15M +$286K +2,700 +7%
CAM
45
Cormorant Asset Management
Massachusetts
$4.14M -$6.09M -57,500 -58%
Dimensional Fund Advisors
46
Dimensional Fund Advisors
Texas
$4.03M +$4.37M +41,252 +39,665%
ProShare Advisors
47
ProShare Advisors
Maryland
$3.34M +$812K +7,668 +29%
Millennium Management
48
Millennium Management
New York
$3.32M -$5.71M -53,978 -61%
TA
49
Teachers Advisors
New York
$3.17M +$249K +2,356 +8%
CS
50
Credit Suisse
Switzerland
$3.14M +$676K +6,382 +25%
1
2
3 4 5

GEVA Hedge Fund Activity: Q1 2015 in Review

130 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) for Q1 2015, worth a combined $3.89B — up 15% from $3.37B a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new GEVA positions and 19 closed out — a net gain of 4 holders — while 56 added to existing stakes and 41 trimmed.

The largest buyer was Baker Bros. Advisors, adding an estimated $106M. The largest seller was Columbia Wanger Asset Management, cutting an estimated $63.7M.

  • 130 institutional investors held SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) as of Q1 2015, up from 126 in Q4 2014.
  • Funds reported $3.89B of SYNAGEVA BIOPHARMA CORP COM STK (DE) stock for Q1 2015, up 15% quarter-over-quarter.
  • 23 funds opened new SYNAGEVA BIOPHARMA CORP COM STK (DE) positions in Q1 2015 and 19 closed out, a net change of +4 holders.
  • The largest SYNAGEVA BIOPHARMA CORP COM STK (DE) buyer in Q1 2015 was Baker Bros. Advisors, an estimated $106M added.
  • The largest SYNAGEVA BIOPHARMA CORP COM STK (DE) seller in Q1 2015 was Columbia Wanger Asset Management, an estimated $63.7M sold.

Based on aggregated 13F filings for Q1 2015.